pre-IPO PHARMA

COMPANY OVERVIEW

MAIA Biotechnology, Inc. is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.maiabiotech.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Sep 29, 2022

MAIA Biotechnology to Present at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics


Sep 8, 2022

MAIA Biotechnology to Participate in H.C. Wainwright 24th Annual Global Investment Conference


Sep 6, 2022

MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022


Aug 30, 2022

MAIA Biotechnology to Present Anticancer THIO Platform at XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids


Aug 22, 2022

MAIA Biotechnology Reports Second Quarter 2022 Financial Results and Provides Corporate Update


For More Press Releases


Google Analytics Alternative